



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MMAD

Cat. No.:	HY-15581
CAS No.:	203849-91-6
Molecular Formula:	C ₄₁ H ₆₆ N ₆ O ₆ S
Molecular Weight:	771.06
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.	



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (129.69 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.2969 mL	6.4846 mL	12.9692 mL
	5 mM		0.2594 mL	1.2969 mL	2.5938 mL
	10 mM		0.1297 mL	0.6485 mL	1.2969 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
IC ₅₀ & Target	Auristatin
In Vitro	MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA